Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

Clinical trial NCT06042647 · COMPLETED

Trial details

NCT number: NCT06042647
Sponsor: Dermatology Consulting Services, PLLC
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Psoriasis Vulgaris

Start date: 2023-07-13
Primary completion: 2023-11-13
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.